Tildrakizumab for Systemic‐Treatment‐Eligible Plaque Psoriasis: A Retrospective Real‐World Study in Chinese Patients
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/9941211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 27.07.2026. Verfasst von Meijiao Xu und 11 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Real‐world data on tildrakizumab in Chinese patients with plaque psoriasis remain limited, particularly in patients treated in routine practice based on systemic treatment eligibility rather than trial‐style severity thresholds.
Objective
To assess the effectiveness and safety of tildrakizumab in Chinese patients with plaque psoriasis over a 28‐week follow‐up period.
Methods
Adults with plaque psoriasis eligible for systemic therapy were enrolled in this multicenter, retrospective, observational study. Psoriasis area and severity index (PASI), body surface area (BSA), and dermatology life quality index (DLQI) were evaluated at baseline, Week 16, and Week 28. Adverse events (AEs) were collected simultaneously.
Results
A total of 59 patients were included (72.9% male, median age 39.0 years), with baseline PASI, BSA, and DLQI of 6.0 ± 6.3, 8.3 ± 10.4%, and 8.2 ± 7.2, respectively. At Week 16, PASI 75, PASI 90, and PASI 100 responses were achieved in 64.3%, 42.9%, and 38.1% of evaluable patients, respectively; corresponding rates at Week 28 were 79.5%, 70.5%, and 54.5%. Absolute PASI targets (PASI ≤ 3 and PASI ≤ 1) were achieved by 90.5% and 66.7% at Week 16, and 97.7% and 81.8% at Week 28, respectively. Mean PASI, BSA, and DLQI all significantly improved from baseline at follow‐up visits. At Week 28, 77.5% of patients achieved DLQI 0/1. In subgroup analyses, biologic‐naïve patients showed higher response rates than biologic‐experienced patients at Week 28, although baseline disease severity differed between groups. AEs occurred in 6.8% of patients and were mild. No patients with latent tuberculosis encountered reactivation.
Conclusions
In this real‐world study, tildrakizumab demonstrated significant effectiveness in Chinese patients with plaque psoriasis eligible for systemic therapy. No new safety signals were observed within the 28‐week follow‐up period.
Zitieren
APA
Xu, M., Zhang, J., Chen, X., Zhang, R., Huang, H., Zhang, B., Zhou, S., Chen, M., Zhou, Q., Xiong, H., Li, M., & Zhang, X. (2026). Tildrakizumab for Systemic‐Treatment‐Eligible Plaque Psoriasis: A Retrospective Real‐World Study in Chinese Patients. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/9941211
Vancouver
Xu M, Zhang J, Chen X, Zhang R, Huang H, Zhang B, et al. Tildrakizumab for Systemic‐Treatment‐Eligible Plaque Psoriasis: A Retrospective Real‐World Study in Chinese Patients. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/9941211
BibTeX
@article{Xu2026,
author = {Xu, Meijiao and Zhang, Jingwen and Chen, Xiaojian and Zhang, Ruochen and Huang, He and Zhang, Bo and Zhou, Shengru and Chen, Min and Zhou, Qianqian and Xiong, Huizi and Li, Min and Zhang, Xuejun},
title = {Tildrakizumab for Systemic‐Treatment‐Eligible Plaque Psoriasis: A Retrospective Real‐World Study in Chinese Patients},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/9941211}
}
EUVIMED